Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 11-14 June 2019
 
Share
News 14/06/2019
PRAC starts review of leuprorelin medicines
EMA’s safety committee () has started a review of leuprorelin medicines after reports indicated that handling errors during preparation and administration can cause some patients to receive insufficient amounts of their medicine, thus reducing the benefits of treatment.
The  will now evaluate all available data and determine whether measures are needed to ensure that the medicines are prepared and administered appropriately.
While the review is ongoing, healthcare professionals should carefully follow the handling instructions for leuprorelin medicines. Patients prescribed these medicines who have any concerns should discuss them with their doctor.
More information is available below.
